ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
뉴포젠(필그라스팀) 시장 규모는 최근 두드러진 성장세를 보이고 있습니다. 2025년 140만 달러에서 2026년에는 148만 달러에 이르고, CAGR 5.5%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 화학요법 사용 확대, 호중구감소증 환자의 높은 감염 위험, g-csf 치료의 임상적 유효성 입증, 병원 중심의 암 치료, 제한된 조기 치료 옵션 등에 기인하는 것으로 보입니다.
뉴포젠(필그라스팀) 시장 규모는 향후 몇 년간 견실한 성장이 전망됩니다. 2030년에는 181만 달러에 이르고, CAGR은 5.2%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 암 발생률 증가, 바이오시밀러 도입 확대, 외래 암 진료 서비스 성장, 생물학적 제제 접근성 개선, 감염 예방에 대한 집중 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 종양학에서 지지요법 사용 증가, 화학요법 유발 호중구감소증 관리 확대, 생물학적 성장인자 사용 증가, 외래 호중구감소증 치료로의 전환, 바이오시밀러 대체품 사용 확대 등을 들 수 있습니다.
다양한 질병의 유병률 증가는 향후 몇 년 동안 뉴포젠(필그라스팀) 시장의 성장을 견인할 것으로 예측됩니다. 질병이란 감염, 유전적 요인, 환경적 요인, 생활습관 등에 의해 유발되는 경우가 많으며, 특정 증상을 일으키거나 특정 부위에 영향을 미치는 신체 구조나 기능의 장애를 말합니다. 이러한 질병 발생률 증가는 고령화, 운동 부족 생활습관, 오염도 증가, 부적절한 식습관, 감염성 병원균의 전 세계적 확산 등의 요인에 의해 촉진되고 있습니다. 뉴포젠(필그라스팀)은 호중구 생성을 촉진하여 화학요법으로 인한 호중구감소증의 합병증 관리를 돕고, 면역기능이 저하된 환자의 감염에 대한 면역체계의 방어능력을 향상시킵니다. 집중 치료를 받는 환자에서 입원율 감소, 감염 위험 관리, 중단 없는 암 치료 계획의 유지에 중요한 역할을 합니다. 예를 들어, 2024년 4월 영국에 기반을 둔 전국적인 자선단체인 Allergy UK의 발표에 따르면, 영국에서 2,100만 명 이상이 알레르기의 영향을 받고 있으며, 2022년에는 알레르기가 가장 많이 보고된 만성 질환이 될 것으로 예측됩니다. 예측에 따르면, 2026년까지 유럽 인구의 절반이 적어도 한 가지 이상의 알레르기를 경험하게 될 것이라고 합니다. 또한, 2022년 6월 영국의 암 지원 단체인 맥밀런 캔서 서포트(Macmillan Cancer Support)는 2022년 현재 영국에 300만 명의 암 환자가 있으며, 2025년까지 약 350만 명, 2030년까지 400만 명에 달할 것이라는 예측을 발표하였습니다. 이처럼 다양한 질환의 유병률 증가가 뉴포젠(필그라스팀) 시장의 성장을 견인하고 있습니다.
헬스케어 연구개발에 대한 정부의 이니셔티브도 뉴포젠(필그라스팀) 시장의 성장을 뒷받침할 것으로 예측됩니다. 이러한 노력은 특정 의료 수요에 대응하고 좋은 결과를 촉진하기 위해 지역, 지역, 국가 또는 국제 수준에서 정부 기관이 시행하는 특정 대상의 행동, 프로그램, 정책 또는 프로젝트를 의미합니다. 여러 정부에서 뉴포젠(필그라스팀)의 개발 및 사용을 지원하는 프로그램을 시행하고 있습니다. 예를 들어, 2023년 5월 영국 보건사회부는 생명과학 분야를 활성화하기 위해 7억 4,909만 달러(6억 5,000만 파운드)의 '성장을 위한 생명과학' 패키지를 발표했습니다. 이 패키지에는 상업적 임상시험 가속화에 1억 3,944만 달러(1억 2,100만 파운드), 영국 바이오뱅크의 역량 확대에 1억 7,747만 달러(1억 5,400만 파운드), 그리고 이 분야에 대한 연기금 투자 유치를 위해 최대 2억 8,811만 달러(2억 5,000만 파운드)의 인센티브가 포함되어 있습니다.(2억 5천만 파운드)의 인센티브가 포함되어 있습니다. 따라서 헬스케어 분야의 정부 연구개발 지원책이 뉴포젠(필그라스팀) 시장의 성장을 견인하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 시장 규제 상황과 투자환경
제29장 경쟁 구도와 기업 개요
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 시장 잠재력이 높은 국가, 부문, 전략
제33장 부록
LSH
영문 목차
영문목차
Neupogen (filgrastim) is a recombinant granulocyte colony-stimulating factor (G-CSF) that promotes the production of white blood cells in the bone marrow. It is used to prevent infections in patients with neutropenia caused by chemotherapy, bone marrow transplantation, or certain medical conditions.
The main forms of Neupogen (filgrastim) are biologic and biosimilar. Biologic drugs are produced from living organisms and involve complex manufacturing processes to achieve specific therapeutic effects. Its indications include chemotherapy-induced neutropenia, chronic neutropenia, and other related conditions. Neupogen is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have influenced the neupogen market by increasing costs for imported biologic raw materials, formulation inputs, and cold-chain transport systems. These pressures have affected hospital and retail pharmacy pricing, especially in regions reliant on imported biologics. Asia-pacific and latin america are among the most affected regions due to limited domestic production capacity. However, tariffs have supported local biosimilar manufacturing, encouraged supplier diversification, and strengthened long-term supply continuity.
The neupogen (filgrastim) market research report is one of a series of new reports from The Business Research Company that provides neupogen (filgrastim) market statistics, including neupogen (filgrastim) industry global market size, regional shares, competitors with a neupogen (filgrastim) market share, detailed neupogen (filgrastim) market segments, market trends and opportunities, and any further data you may need to thrive in the neupogen (filgrastim) industry. This neupogen (filgrastim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The neupogen (filgrastim) market size has grown strongly in recent years. It will grow from $1.4 million in 2025 to $1.48 million in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to growth in chemotherapy utilization, high infection risk in neutropenic patients, clinical validation of g-csf therapy, hospital-centered cancer care, limited early treatment options.
The neupogen (filgrastim) market size is expected to see strong growth in the next few years. It will grow to $1.81 million in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing cancer incidence, expansion of biosimilar adoption, growth in outpatient oncology services, improved access to biologic therapies, focus on infection prevention. Major trends in the forecast period include rising use of supportive care in oncology, expansion of chemotherapy-induced neutropenia management, increased adoption of biologic growth factors, shift toward outpatient neutropenia treatment, growing use of biosimilar alternatives.
The increasing prevalence of various diseases is expected to drive the growth of the Neupogen (filgrastim) market in the coming years. Diseases are disruptions in the structure or function of the body that produce specific symptoms or affect certain areas, often caused by infections, genetics, environmental factors, or lifestyle choices. The rising occurrence of these conditions is fueled by factors such as aging populations, sedentary lifestyles, higher pollution levels, poor dietary habits, and the global spread of infectious pathogens. Neupogen (filgrastim) helps manage complications from chemotherapy-induced neutropenia by stimulating neutrophil production, thereby enhancing the immune system's ability to fight infections in immunocompromised patients. It plays a key role in reducing hospitalizations, managing infection risks, and supporting uninterrupted cancer treatment regimens for patients undergoing intensive therapies. For example, in April 2024, Allergy UK, a UK-based national charity, reported that over 21 million people in the UK were affected by allergies, making it the most commonly reported chronic condition in 2022, with projections suggesting that by 2026, half of Europe's population will experience at least one allergy. Additionally, in June 2022, Macmillan Cancer Support, a UK-based cancer charity, reported that 3 million people were living with cancer in the UK in 2022, with projections reaching nearly 3.5 million by 2025 and 4 million by 2030. Therefore, the rising prevalence of various diseases is driving the Neupogen (filgrastim) market.
Government initiatives in healthcare research and development are also expected to support the growth of the Neupogen (filgrastim) market. Such initiatives refer to targeted actions, programs, policies, or projects undertaken by governmental bodies at local, regional, national, or international levels to address specific healthcare needs and drive positive outcomes. Several governments are implementing programs to support aspects of Neupogen (filgrastim) development and use. For example, in May 2023, the UK Department of Health and Social Care announced a $749.09 million (£650 million) "Life Sci for Growth" package to boost the life sciences sector. This package included $139.44 million (£121 million) to accelerate commercial clinical trials, $177.47 million (£154 million) to expand the UK Biobank's capabilities, and incentives of up to $288.11 million (£250 million) to attract pension-fund investment into the sector. Therefore, government initiatives for research and development in healthcare are driving the Neupogen (filgrastim) market.
Leading companies in the Neupogen (filgrastim) market are increasingly developing innovative filgrastim biosimilars to offer cost-effective and accessible alternatives for treating chemotherapy-induced neutropenia. Filgrastim biosimilars are biologic medicines that closely replicate the original Neupogen in terms of safety, efficacy, and structure, primarily used to stimulate neutrophil production in chemotherapy patients to prevent neutropenia. For instance, in September 2024, Tanvex BioPharma, a US-based biopharmaceutical company, received FDA approval for Nypozi (filgrastim-txid), a biosimilar referencing Amgen's Neupogen. Nypozi was one of three biosimilars approved by the FDA on the same day, contributing to a total of 55 biosimilars cleared in the United States as of June 2024. It is indicated to reduce the incidence of infection, as evidenced by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.
Major companies operating in the neupogen (filgrastim) market are Amgen Inc.
North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the neupogen (filgrastim) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
The neupogen (filgrastim) market consists of sales of formulations, pre-filled syringes, vials for injection, and long-acting pegylated G-CSF derivatives. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Neupogen (filgrastim) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses neupogen (filgrastim) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for neupogen (filgrastim) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neupogen (filgrastim) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Type: Biologic; Biosimilar
2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
5. Neupogen (filgrastim) Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Oncology Clinics
5.3 Specialty Cancer Centers
5.4 Outpatient Care Centers
5.5 Bone Marrow Transplant Units
6. Neupogen (filgrastim) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Neupogen (filgrastim) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Neupogen (filgrastim) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Neupogen (filgrastim) Market Size, Comparisons And Growth Rate Analysis
7.3. Global Neupogen (filgrastim) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Neupogen (filgrastim) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Neupogen (filgrastim) Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Neupogen (filgrastim) Market Segmentation
9.1. Global Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Biologic, Biosimilar
9.2. Global Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Neupogen (filgrastim) Market
12.1. China Neupogen (filgrastim) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Neupogen (filgrastim) Market
13.1. India Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Neupogen (filgrastim) Market
14.1. Japan Neupogen (filgrastim) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Neupogen (filgrastim) Market
15.1. Australia Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. South Korea Neupogen (filgrastim) Market
16.1. South Korea Neupogen (filgrastim) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
16.2. South Korea Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. Western Europe Neupogen (filgrastim) Market
17.1. Western Europe Neupogen (filgrastim) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. Western Europe Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. UK Neupogen (filgrastim) Market
18.1. UK Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. Germany Neupogen (filgrastim) Market
19.1. Germany Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. France Neupogen (filgrastim) Market
20.1. France Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. Eastern Europe Neupogen (filgrastim) Market
21.1. Eastern Europe Neupogen (filgrastim) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
21.2. Eastern Europe Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. North America Neupogen (filgrastim) Market
22.1. North America Neupogen (filgrastim) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
22.2. North America Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. USA Neupogen (filgrastim) Market
23.1. USA Neupogen (filgrastim) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
23.2. USA Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
24.2. Canada Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. South America Neupogen (filgrastim) Market
25.1. South America Neupogen (filgrastim) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
25.2. South America Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Middle East Neupogen (filgrastim) Market
26.1. Middle East Neupogen (filgrastim) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Middle East Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Africa Neupogen (filgrastim) Market
27.1. Africa Neupogen (filgrastim) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
27.2. Africa Neupogen (filgrastim) Market, Segmentation By Drug Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. Neupogen (filgrastim) Market Regulatory and Investment Landscape
29. Neupogen (filgrastim) Market Competitive Landscape And Company Profiles
29.1. Neupogen (filgrastim) Market Competitive Landscape And Market Share 2024
29.1.1. Top 10 Companies (Ranked by revenue/share)
29.2. Neupogen (filgrastim) Market - Company Scoring Matrix
29.2.1. Market Revenues
29.2.2. Product Innovation Score
29.2.3. Brand Recognition
29.3. Neupogen (filgrastim) Market Company Profiles
29.3.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
30. Global Neupogen (filgrastim) Market Competitive Benchmarking And Dashboard
31. Key Mergers And Acquisitions In The Neupogen (filgrastim) Market
32. Neupogen (filgrastim) Market High Potential Countries, Segments and Strategies
32.1 Neupogen (filgrastim) Market In 2030 - Countries Offering Most New Opportunities
32.2 Neupogen (filgrastim) Market In 2030 - Segments Offering Most New Opportunities
32.3 Neupogen (filgrastim) Market In 2030 - Growth Strategies
32.3.1 Market Trend Based Strategies
32.3.2 Competitor Strategies
33. Appendix
33.1. Abbreviations
33.2. Currencies
33.3. Historic And Forecast Inflation Rates
33.4. Research Inquiries
33.5. The Business Research Company
33.6. Copyright And Disclaimer
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
